ライフサイエンスコーパス: TLR8

1 gnition receptor (PRR) Toll-like receptor 8 (TLR8).

2 requisites governing activity at TLR7 and/or TLR8.

3 s, confirming its high selectivity for human TLR8.

4 ic mice expressing different levels of human TLR8.

5 ecently described crystal structure of human TLR8.

6 through Toll like Receptors (TLR)3, TLR7 and TLR8.

7 was maximally antagonistic at both TLR7 and TLR8.

8 hages expressing both intracellular TLR7 and TLR8.

9 s for the first and second binding pocket of TLR8.

10 he ligands for Toll-like receptor (TLR)7 and TLR8.

11 r natural guanosine activated human TLR7 and TLR8.

12 the RNA-derived molecular pattern sensed by TLR8.

13 lines can selectively activate human TLR7 or TLR8.

14 nded, exogenous RNA molecules detectable for TLR8.

15 ized for their activity and selectivity over TLR8.

16 intracellular receptor in human subjects is TLR8.

17 nists depicted excellent selectivity against TLR8.

18 TLR8 1A/G reduced disease progression.

19 ted by 3M-002 (TLR8 agonist) and resiquimod (TLR8/7 agonist).

20 that activate TLR8 (R-848; (TLR7/8) CL075; (TLR8/7)), with respect to activation of human newborn an

21 2L:Pam3CSK4, TLR5L:flagellin, TLR4L:LPS, and TLR8/7L:CL075 also blocked Treg suppression of CD4(+) or

22 On the cellular level, TLR8(-/-) and TLR8/9(-/-) dendritic cells were hyperesponsive to TLR7

23 Moreover, B cells from TLR9(-/-) and TLR8/9(-/-) mice were hyperesponsive to R848, but TLR8(-

24 ere, we reveal that double TLR8/9-deficient (TLR8/9(-/-)) mice on the C57BL/6 background showed incre

25 Here, we reveal that double TLR8/9-deficient (TLR8/9(-/-)) mice on the C57BL/6 backg

26 blood, consistent with an active circulating TLR8/9-stimulating factor.

27 blood mononuclear cells, but only TLR7- and TLR8-activating compounds activated plasmacytoid dendrit

28 Additionally, TLR7- and TLR8-activating compounds, but not the compounds that ac

29 e protease granzyme B upon both FcgammaR and TLR8 activation.

30 TLR7, but not TLR8, activation of monocytes also stimulated Ca(2+) flu

31 lper 1-polarizing cytokines, suggesting that TLR8-active compounds may be promising candidate adjuvan

32 In an effort to identify novel dual TLR7/TLR8-active compounds, we undertook structure-activity r

33 es permitted the classification of inactive, TLR8-active, and TLR7/8 dual-active compounds, confirmin

34 ion in mononuclear phagocytes by suppressing TLR8 activity and this particular function of FANCC is i

35 ently described scaffolds that have residual TLR8 activity, which may be detrimental to the tolerabil

36 s ratio [aGMR], 1.15; 95% CI, 1.02-1.30) and TLR8 (aGMR, 1.15; 95% CI, 1.04-1.26).

37 Potent TLR8 agonism (IL-12p40 EC(50) = 220 nM) and >100-fold TL

38 However, a combination of polyT ODN plus the TLR8 agonist activated NF-kappaB, whereas polyT ODN plus

39 Immunogenicity of the TLR8 agonist adjuvanted antigen 85B (Ag85B)/peptide 25-l

40 ves, TLR7-deficient mice are unresponsive to TLR8 agonist IRMs.

41 l immune response, and therefore a selective TLR8 agonist may be an effective treatment option.

42 Remarkably, TLR8 agonist polymersomes induced not only newborn DC ma

43 VTX-294 is a novel ultra-potent TLR8 agonist that activates newborn and adult leukocytes

44 tuximab-coated tumor targets was enhanced by TLR8 agonist treatment, and this enhancement of ADCC req

45 r, we found that LC are activated by 3M-002 (TLR8 agonist) and resiquimod (TLR8/7 agonist).

46 cterize polymer nanocarriers encapsulating a TLR8 agonist, allowing direct intracellular release afte

47 odo-6-methylpyrimidine-2,4-diamine as a pure TLR8 agonist, and a detailed structure-activity relation

48 o[d]imidazol-2-amine, was found to be a pure TLR8 agonist, evoking strong proinflammatory cytokine an

49 We demonstrate that a selective TLR8 agonist, in combination with FLT3L, primes high-qua

50 djuvant, with or without a TLR7/8 agonist, a TLR8 agonist, or the TLR9 ligand cytosine phosphate guan

51 timulatory activities of a novel benzazepine TLR8 agonist, VTX-294, in comparison to imidazoquinoline

52 subcutaneous injection to neonatal mice, the TLR8 agonist-adjuvanted Ag85B peptide 25 formulation was

53 rrow-derived DCs enabled benchmarking of the TLR8 agonist-encapsulating polymersome formulations agai

54 uptake by murine DCs in vivo, and a range of TLR8 agonist-encapsulating polymersome formulations were

55 TLR8 agonist-encapsulating polymersomes hold substantial

56 The ontogeny of TLR8 agonist-induced cytokine responses was defined in r

57 at the same time with either of the TLR7 or TLR8 agonist.

58 mine was found to be a very potent dual TLR7/TLR8 agonist.

59 lective TLR7 antagonists without any TLR7 or TLR8 agonistic activity.

60 compounds have been tested for their TLR7 or TLR8 agonistic and antagonistic activities.

61 esent a novel, alternate chemotype with pure TLR8-agonistic activities and will likely prove useful n

62 We observed a pure TLR8-agonistic activity profile in select furo[2,3-c]qui

63 nopropyl appendages at C5 displayed dominant TLR8-agonistic activity.

64 TLR8 agonists also effectively induced up-regulation of

65 LR8 that does not respond to any known human TLR8 agonists also inhibits both murine and human TLR7.

66 TLR8 agonists are more effective than other TLR agonists

67 We conclude that TLR8 agonists are uniquely efficacious in activating cos

68 mice overexpressed TNF-alpha in response to TLR8 agonists but not other TLR agonists.

69 esion clearance may differ and that TLR7 and TLR8 agonists can reduce the frequency of mucosal HSV-2

70 The strong activity of TLR8 agonists correlates with their induction of p38 MAP

71 eting ASOs can be selected to synergize with TLR8 agonists currently under investigation as immunothe

72 Interestingly, some of the TLR7 and/or TLR8 agonists differed in their ability to activate glia

73 Treatment with TLR8 agonists elicited granzyme B and also enhanced Fcga

74 IMQ TLR8 agonists engage adenosine-refractory TLR8 and infla

75 erebroventricular inoculation of TLR7 and/or TLR8 agonists in newborn mice.

76 Incorporation of TLR3 and TLR8 agonists into the CD40L/IFN-gamma activation protoc

77 Dual TLR7/TLR8 agonists markedly upregulate CD80 expression in mul

78 but little is known about whether different TLR8 agonists may distinctly activate neonatal leukocyte

79 nd have uncovered another mechanism by which TLR8 agonists may enhance FcgammaR-based therapies.

80 The TLR8 agonists polyuridylic acid and polyadenylic acid al

81 dy, we examined the potential of TLR7 and/or TLR8 agonists to induce glial activation and neuroinflam

82 ld be considerably more favorable than other TLR8 agonists under evaluation.

83 acholine in vitro, and responses to TLR7 and TLR8 agonists were assessed.

84 TLR8 agonists, including imidazoquinolines (IMQs), such

85 We now show that TLR8 agonists, including R-848 (TLR7/8), the imidazoquin

86 HEK293 cells transfected with murine TLR7 or TLR8 and a NF-kappaB luciferase reporter, we demonstrate

87 ociations exist between genetic variation in TLR8 and AR.

88 TLR8 and inflammasome function were assayed by using sma

89 MQ TLR8 agonists engage adenosine-refractory TLR8 and inflammasome pathways to induce robust monocyte

90 This occurs through TLR8 and leads to the production of TNF-alpha and IL-6,

91 Human TLR7 and TLR8 and mouse TLR7 recognize viral ssRNA motifs and ind

92 udy, we transfected HEK293 cells with murine TLR8 and NF-kappaB reporter constructs and stimulated th

93 pha production in mutant cells depended upon TLR8 and the canonical downstream signaling intermediate

94 Triggering of Toll-like receptor (TLR) 4 or TLR8 and the proinflammatory cytokines IL-1beta or IL-6

95 and TLR9 control TLR7 function, but whether TLR8 and TLR9 act in parallel or in series in the same o

96 Thus, both TLR8 and TLR9 control TLR7 function, but whether TLR8 an

97 These results reveal that TLR8 and TLR9 have an additive effect on controlling TLR

98 ic ligands for TLR2, TLR3, TLR4, TLR5, TLR7, TLR8 and TLR9 in the presence or absence of telomeric ol

99 t TASL is an innate immune adaptor for TLR7, TLR8 and TLR9 signalling, revealing a clear mechanistic

100 enting cells through the RNA and DNA sensors TLR8 and TLR9.

101 that respond to viral infection, TLR3, TLR7, TLR8 and TLR9.

102 On the cellular level, TLR8(-/-) and TLR8/9(-/-) dendritic cells were hyperespo

103 e toll-like receptor system (TLR4, TLR7, and TLR8) and inflammasome complex pathway (NLRP3, NLRC4, an

104 ions of the endovesicular Toll-like receptor TLR8, and the inflammasome protein NAcht leucine-rich re

105 ts displayed dysregulated responses to TLR4, TLR8, and TLR7 stimulation.

106 activate the innate immune system via TLR7, TLR8, and TLR7/8, respectively.

107 Destruction of YxxPhi abolished TLR7, TLR8, and TLR9 activity toward nucleic acids in human B

108 b(+) cells that respond to TLR2, TLR4, TLR7, TLR8, and TLR9 agonists as measured by the secretion of

109 ILshort production are type I IFNs and TLR7, TLR8, and TLR9 agonists.

110 show that in CD4(+) T cells, NA-TLRs, TLR3, TLR8, and TLR9 are upregulated by FcgammaRIIIa-pSyk cosi

111 Among the 11 human TLRs, a subfamily TLR7, TLR8, and TLR9 display similarities in structure and end

112 fter exposure to Toll-like receptor (TLR) 2, TLR8, and TLR9 ligands, further supporting an important

113 Hence, TLR7, TLR8, and TLR9 may prevent the recruitment of developing

114 Toll-like receptor (TLR)7, TLR8, and TLR9 sense microbial or endogenous nucleic aci

115 lar PRRs such as endosomal TLRs (TLR3, TLR7, TLR8, and TLR9) and cytoplasmic proteins (absent in mela

116 or several TLRs, including TLR3, TLR4, TLR7, TLR8, and TLR9, have been or are being developed for the

117 atory DNA sequences (IRSs) specific to TLR7, TLR8, and TLR9, we show that the TLR8 inhibitor IRS957 s

118 er localization of intracellular TLR3, TLR7, TLR8, and TLR9.

119 icient cells are unresponsive to TLR3, TLR7, TLR8, and TLR9.

120 sely related and highly homologous are TLR7, TLR8, and TLR9.

121 effects of one TLR on the other among TLR7, TLR8, and TLR9.

122 Herein, the development of a TLR8 antagonist competition assay and its application fo

123 Demonstrating that TLR7 and TLR8 are expressed on human LC, we hypothesized that imi

124 Rare variants in TLR8 are not associated with AR.

125 quent downstream signaling by human TLR7 and TLR8 are unknown.

126 Other receptors (in addition to TLR7 and TLR8) are likely to be found, but this is the first iden

127 nd overexpression, we unambiguously identify TLR8 as receptor for bacterial RNA in primary human mono

128 noline congeners 3M-003 (TLR7/8) and 3M-002 (TLR8), as well as single-stranded viral RNAs (TLR8) indu

129 n mutant cells, we confirmed that TLR8 (or a TLR8-associated protein) is ubiquitinylated in mutant FA

130 tiated HL-60 cells express RIG-I, MDA-5, and TLR8 at the mRNA and protein levels, whereas TLR3 and TL

131 by activating a previously unexplored miR21/TLR8 axis that sustains cancer malignancy.

132 9(-/-) mice were hyperesponsive to R848, but TLR8(-/-) B cells were not.

133 pharmacokinetic (PK) properties and improved TLR8 binding affinity.

134 The TLR8-ectodomain:(R)-7 complex confirmed TLR8 binding and a direct ligand interaction with TLR8 r

135 Taken together in human macrophages, TLR8 binds and internalizes HIV ssRNA, leading to endoso

136 A3hi DCs respond to poly I:C and agonists of TLR8, but not of TLR7, and produce interleukin (IL)-12 w

137 compared with linear RNA and activated human TLR8, but not TLR7, in HEK293 cells without using lipid

138 signaling (SOCS)-1 directly associated with TLR8, but not with TLR7, indicating a novel role for TLR

139 eporter, we demonstrated that stimulation of TLR8-, but not TLR7-, transfected cells with either VV o

140 Our data suggest TLR7 and TLR8 can signal in two different "modes" depending on th

141 t led to the identification of the selective TLR8 clinical candidate (R)-2-((2-amino-7-fluoropyrido[3

142 mical assay in combination with cellular and TLR8 cocrystal structural data resulted in the identific

143 ream inflammatory signaling in response to a TLR8 cognate ssRNA ligand.

144 Furthermore, knockdown of TLR8 completely attenuated collagen expression in monocy

145 disease and other diseases that might have a TLR8 component, including cancer.

146 TLR8 controls TLR7 function on dendritic cells, and TLR9

147 Collectively, we report that TLR8 coupling with SOCS-1 inhibits TLR7-mediated antivir

148 In this article, we report that TLR8-deficient (Tlr8(-/-)) mice were resistant to WNV in

149 Moreover, TLR8-dependent detection of bacterial RNA was critical f

150 r BIRB 796 and dasatinib potently suppressed TLR8-dependent expression of the reporter gene.

151 eotides were capable of activating pDCs in a TLR8-dependent manner.

152 Several analogues were found to activate TLR8-dependent NF-kappaB signaling.

153 T2 as a non-redundant upstream component of TLR8-dependent RNA recognition.

154 dendritic cells as well as the production of TLR8-dependent type II interferon (IFN-gamma), TNF-alpha

155 The responses induced by F-HIV were TLR8-dependent with subsequent activation of IFN regulat

156 IFN-gamma and TNF-alpha induction is largely TLR8-dependent.

157 mpounds that activates TLR8 or both TLR7 and TLR8 depending on the nucleotide composition and chemica

158 f Snapin enhanced localization of HIV-1 with TLR8(+) early endosomes, triggered a pro-inflammatory re

159 The TLR8-ectodomain:(R)-7 complex confirmed TLR8 binding and

160 response to TLR1/2, TLR2/6, TLR3, TLR5, and TLR8 engagement in mDCs and TLR7 and TLR9 in pDCs.

161 TLR8 engages two distinct ligand binding sites to sense

162 Activation of human toll-like receptor-8 (TLR8) evokes a distinct cytokine profile favoring the ge

163 infrequent, and TLR1, TLR3, TLR5, TLR6, and TLR8 expressed in selective patterns.

164 vation, and that siRNA-mediated knockdown of TLR8 expression in pDCs led to a complete ablation of VV

165 We previously reported that TLR8 expression was increased directly by the tumor supp

166 th systemic arthritis and the correlation of TLR8 expression with the elevation of IL-1beta levels an

167 ethylation of histone 3 at lysine 4, whereas TLR8 gene knockdown reduced these effects.

168 Either MYD88 or TLR8 gene knockdown with relevant siRNA reduced HIV-1 ss

169 The TLR8 gene was resequenced in 288 AR patients from Malmo

170 The Toll-like receptor 8 (TLR8) has an important role in innate immune responses t

171 TLR8 IMQs induced robust TNF and IL-1beta in whole blood

172 adult monocytes and MoDCs, signaling through TLR8 in an adenosine/cyclic AMP-refractory manner.

173 However, the role of mouse TLR8 in antiviral immunity is poorly understood.

174 Crystal structures of TLR8 in complex with the two most active compounds confi

175 Agonist stimulation of TLR8 in cultured cortical neurons causes inhibition of n

176 a new mechanism of innate immune sensing by TLR8 in DCs, which is exploited by HIV-1 to promote tran

177 converts self-RNA into a trigger of TLR7 and TLR8 in human DCs, and provide new insights into the mec

178 A pathogenic role for TLR8 in human diseases was suggested by its increased ex

179 ind to toll-like receptors (TLR7 in mice and TLR8 in human) expressed by the immune cells.

180 diseases that may benefit from inhibition of TLR8 in humans.

181 Studies on the role of the RNA receptor TLR8 in inflammation have been limited by its different

182 s TLR7 and TLR9 in human dendritic cells and TLR8 in monocytes.

183 RNA receptors RIG-I, MDA-5, TLR3, TLR7, and TLR8 in primary neutrophils and immortalized neutrophil-

184 s a cooperative interaction between TLR2 and TLR8 in pro- and antiinflammatory cytokine responses, wh

185 rus and highlight the importance of TLR7 and TLR8 in that response.

186 These findings reveal novel functions for TLR8 in the mammalian nervous system that are distinct f

187 61624) in the TLR8 promoter, thereby placing TLR8 in the p53/immune axis.

188 r study demonstrates a physiological role of TLR8 in the sensing of entire S. aureus in human primary

189 an anti-HCV immune response through TLR7 and TLR8 in various antigen presenting cells.

190 ergent suppression of TLR7 and activation of TLR8, in a sequence-dependent manner.

191 receptor (TLR) family, murine TLR7 and human TLR8, in immune cells, triggering a TLR-mediated prometa

192 aining compound that activated both TLR7 and TLR8 induced IFN-alpha in monkeys.

193 LR8), as well as single-stranded viral RNAs (TLR8) induced robust production of the Th1-polarizing cy

194 ic to TLR7, TLR8, and TLR9, we show that the TLR8 inhibitor IRS957 significantly diminishes productio

195 The results indicate that TLR8 inhibits TLR7 and TLR9, and TLR9 inhibits TLR7 but

196 TLR8 -: IRF5 signaling was necessary for induction of IF

197 TLR8 is among the highest-expressed pattern-recognition

198 emonstrate that the sequence motif sensed by TLR8 is clearly distinct from that recognized by TLR13.

199 We report that TLR8 is dynamically expressed during mouse brain develop

200 poly(A)/T-rich DNA in pDCs, and that murine TLR8 is functional in the context of a viral infection.

201 y demonstrates for the first time that mouse TLR8 is functional.

202 rine TLR8, leading to the belief that murine TLR8 is nonfunctional.

203 y, our data are unique in demonstrating that TLR8 is required for sensing poly(A)/T-rich DNA in pDCs,

204 antiinflammatory cytokine responses, whereas TLR8 is solely responsible for IRF7-mediated induction o

205 Because TLR8 is X-linked, the increases were generally reduced i

206 erved for polymorphisms in TLR2, TLR4, TLR6, TLR8, ITGAV, ITGB3, ITGAM, and TIRAP.

207 ion into MPhis could be prevented by TLR7 or TLR8 knockdown.

208 ilarly, natural ssRNA cannot activate murine TLR8, leading to the belief that murine TLR8 is nonfunct

209 TLR8 ligands induced IKKgamma phosphorylation, whereas I

210 TLR8 ligands trigger similar levels of IkappaBalpha phos

211 were required for these cells to respond to TLR8 ligands, whereas TAK1, JNK, and ERK molecules did n

212 R7 and TLR9, but not to TLR2, TLR4, TLR5 and TLR8 ligands.

213 IL-1 were not detected in cells treated with TLR8 ligands.

214 on) were not detected in cells stimulated by TLR8 ligands.

215 Drugs targeting macrophage TLR8-linked signaling pathways may modulate the innate i

216 detected a number of significant SNPs in the TLR8 locus.

217 The TLR8-mediated activation of IRF5 was dependent on TAK1 a

218 On the other hand, TLR8-mediated IkappaBalpha phosphorylation, NF-kappaB, a

219 We conclude that p53 can strongly influence TLR8-mediated immune responses and that knowledge of the

220 n induced the expression of pro-IL-1beta via TLR8-mediated mechanisms and activated caspase-1 through

221 We postulate that TLR8-mediated MEKK3-dependent IKKgamma phosphorylation m

222 Our evidence indicates that such TLR8-mediated neuronal responses do not involve the cano

223 The differences between IL-1R- and TLR8-mediated NF-kappaB activation are also reflected at

224 how significant effects on TLR3-, TLR7-, and TLR8-mediated NF-kappaB activation.

225 TLR8-mediated NF-kappaB and IRF7 activation are abolishe

226 ts of IRAK and IRAK4, respectively, restored TLR8-mediated NF-kappaB and IRF7 activation in the IRAK-

227 The above results indicate that although TLR8-mediated NF-kappaB and JNK activation are IRAK-depe

228 The production of IFN-beta was induced by TLR8-mediated sensing of S. aureus RNA, which triggered

229 of IRAK and IRAK4 is probably redundant for TLR8-mediated signaling.

230 We recently found that TLR8 mediates a unique NF-kappaB activation pathway in h

231 eptibility to WNV-mediated neuronal death in Tlr8(-/-) mice were attributed to overexpression of Tlr7

232 this article, we report that TLR8-deficient (Tlr8(-/-)) mice were resistant to WNV infection compared

233 ibe the syntheses and evaluation of TLR7 and TLR8 modulatory activities of dimeric constructs of imid

234 tal human monocyte-derived DCs and humanized TLR8 mouse bone marrow-derived DCs enabled benchmarking

235 urified NK cells despite their expression of TLR8 mRNA and protein.

236 In vivo, TLR8-MyD88-dependent pDC activation played a critical ro

237 ion was evaluated in vivo by using humanized TLR8 neonatal mice.

238 appropriate activation of endosomal TLR7 and TLR8 occurs in several autoimmune diseases, in particula

239 ndence of the selectivity for TLR7 vis-a-vis TLR8 on the electronic configurations of the heterocycli

240 ulatory RNA (SIMRA) compounds that activates TLR8 or both TLR7 and TLR8 depending on the nucleotide c

241 ated only in mutant cells, we confirmed that TLR8 (or a TLR8-associated protein) is ubiquitinylated i

242 ls, and renal pathology compared with single TLR8(-/-) or TLR9(-/-) mice.

243 by Toll-like receptor members TLR3, TLR7 and TLR8, or by the RNA helicases RIG-I (also known as DDX58

244 In mice TLR7-deficiency ameliorates SLE, but TLR8- or TLR9-deficiency exacerbates the disease because

245 acuole, whereas recruitment of both TLR2 and TLR8 overlaps with degradation of the spirochete.

246 elated to immune function and transcription (TLR8, P = .0002; DAPP1, P = .0003; LAMP3, P = 9.96E(-05)

247 mmune defenses (e.g., RIG-1, MDA-5, TLR7 and TLR8, PKR, APOBEC3B, 3F, 3G), adaptive immunity, and in

248 Surprisingly, TLR8 potentiation by the gapmer ASOs was blunted by lock

249 eotide polymorphism (SNP) (rs3761624) in the TLR8 promoter, thereby placing TLR8 in the p53/immune ax

250 omparison to imidazoquinolines that activate TLR8 (R-848; (TLR7/8) CL075; (TLR8/7)), with respect to

251 mally to all TLR1/2, TLR2/6, TLR4, TLR7, and TLR8 (R848) agonists tested, and to IL-1beta.

252 Toll-like receptors TLR7 and TLR8 recognize specific intracellular viral ssRNA sequen

253 Toll-like receptor 8 (TLR8) recognizes pathogen-derived single-stranded RNA fr

254 therefore searches for rare variants in the TLR8 region and also investigates the reproducibility of

255 t not with TLR7, indicating a novel role for TLR8 regulation of SOCS-1 function, whereas selective sm

256 ptor proteins Toll-like receptor (TLR) 7 and TLR8 reportedly results in male-biased litters by select

257 binding and a direct ligand interaction with TLR8 residue Asp545.

258 The modulation of TLR7 and TLR8 responses is independent of CpG motifs or the natur

259 cids in human B cells and monocytes, whereas TLR8 responses toward small molecules remained intact.

260 s and activates dendritic cells via TLR7 and TLR8, resulting in the activation of the NF-kappaB pathw

261 that the consequence of self-recognition via TLR8 results in a constellation of diseases, strikingly

262 ression of Toll-like receptor (TLR) 3, TLR7, TLR8, retinoic acid-inducible gene I (RIG-I), melanoma d

263 incubation with an ssRNA ligand, as well as TLR8 RNA and protein expression along with p53 binding a

264 CG, P = 0.02, OR 0.30, 95% CI 0.11-0.85) and TLR8-rs3764879 (CC versus GG and CG, P = 0.02, OR 0.31,

265 5743611, TLR4-rs7873784, TLR7-rs3853839, and TLR8-rs3764879 and susceptibility to periodontitis in ad

266 The "G-G" haplotype of TLR7 rs3853839 and TLR8 rs3764880 increased risk of SLE in females (age adj

267 TLR7 rs3853839-G (G vs. C: p = 0.0100) and TLR8 rs3764880-G (recessive model: p = 0.0173; additive

268 igned oligonucleotides strongly potentiating TLR8 sensing of Resiquimod, which preserve TLR7 function

269 yte-derived dendritic cells here showed that TLR8 sensing of RNA ORN versus imidazoquinoline translat

270 and suppressor function could be blocked by TLR8 signaling and/or by specific ERK1/2 and p38 inhibit

271 ikely prove useful not only in understanding TLR8 signaling but also perhaps as a candidate vaccine a

272 at poly(T) ODNs can inhibit TLR7 and enhance TLR8 signaling events involving NF-kappaB activation in

273 dition, we demonstrated that manipulation of TLR8 signaling in gammadelta Treg cells can block gammad

274 Snapin inhibited TLR8 signaling in the absence of HIV-1 and is a general

275 Of particular interest, the human TLR8 signaling pathway is essential for reversing the su

276 fic gammadelta T cells and identify a unique TLR8 signaling pathway linking to their functional regul

277 This modulation of TLR8 signaling was mediated by complement receptor 3 and

278 3-pentyl-quinoline-2-amine as a novel, human TLR8-specific agonist.

279 lactis G121-treated human DCs was blocked by TLR8-specific inhibitors, mediated by L lactis G121 RNA,

280 s, but not the compounds that activated only TLR8, stimulated mouse immune cells in vitro and in vivo

281 Furthermore, TLR7 or TLR8 stimulation, independent of HCV, caused monocyte di

282 monocytes with a higher response to TLR4 and TLR8 stimulations in obesity.

283 TX-294 was approximately 100x more active on TLR8- than TLR7-transfected HEK cells (EC50, approximate

284 The murine TLR8 that does not respond to any known human TLR8 agoni

285 n showed antagonistic activities at TLR7 and TLR8; the C2 dimer with a propylene spacer was maximally

286 healthy skin, in complex with LL37 triggered TLR8/TLR13-mediated cytokine and NET release by PMNs in

287 scription of TLR3, bditTLR4, TLR5, bditTLR7, TLR8, TLR9, and TLR10 upon Abeta stimulation is severely

288 degradation is extended to TLR3, TLR6, TLR7, TLR8, TLR9, and TLR10, whereas the cellular level of TLR

289 ubiquitous kinase, IRAK1, TLR1, TLR4, TLR6, TLR8, TLR9, and TNFR-associated factor 6) were downregul

290 r 2)-engaged and TLR7 (Toll-like receptor 7)/TLR8 (Toll-like receptor 8)-engaged CD14(+) monocytes wi

291 monstrates that in human monocytes, TLR7 and TLR8 triggered different signaling pathways that contrib

292 cross-talk between ODNs, IRMs, and TLR7 and TLR8 uncovered by this study may have practical implicat

293 Finding that Toll-like receptor 8 (TLR8) was one of the proteins ubiquitinylated only in mu

294 Toll-like receptor 8 (TLR8) was required for inducing pro-IL-1beta expression,

295 Seven previously AR-associated SNPs from TLR8 were analyzed for AR associations in 422 AR patient

296 Six SNPs of TLR3, TLR7, and TLR8 were genotyped to determine their associations with

297 TLR7 and TLR8 were identified as eliciting antiviral effects when

298 lated monocytes is greater for TLR2 than for TLR8, whereas expression of both TLRs increases signific

299 at live Bb induces transcription of TLR2 and TLR8, whereas IRS957 interferes with their transcription

300 pecific and differentially involved TLR7 and TLR8, which sense single-stranded RNA.